Halozyme Therapeutics (HALO) News Today $65.20 -0.82 (-1.24%) Closing price 04:00 PM EasternExtended Trading$64.90 -0.30 (-0.45%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Halozyme Therapeutics Down Today?Toggle Visibility of Why Is Halozyme Therapeutics Down Today?Halozyme Therapeutics (NASDAQ:HALO) shares are trading lower today as investors weigh a mix of analyst updates and company developments. Positive Sentiment: Halozyme announced its planned acquisition of Elektrofi to integrate Hypercon technology into its drug-delivery platform, aiming to support long-term growth. Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth? Positive Sentiment: Zacks Research analysts boosted their Q1 2026 EPS estimate to $1.00 from $0.94, reflecting upward revision momentum. Zacks Research Analysts Increase Earnings Estimates for HALO Positive Sentiment: Zacks Research raised its Q2 2026 EPS forecast to $1.28 from $1.24 while maintaining a “Strong-Buy” rating. Halozyme Therapeutics Q2 2026 EPS Estimate Revision Positive Sentiment: Analysts at Zacks lifted their Q3 2026 EPS estimate to $1.49 from $1.43, reaffirming a “Strong-Buy” view. Halozyme Therapeutics Q3 2026 EPS Estimate Revision Positive Sentiment: Zacks Research increased its Q2 2027 EPS projection to $1.48 from $1.41, maintaining a “Strong-Buy” stance. Halozyme Therapeutics Q2 2027 EPS Estimate Revision Positive Sentiment: Zacks Research boosted the FY 2026 EPS outlook to $5.75 from $5.59 and reaffirmed a “Strong-Buy” rating. Halozyme Therapeutics FY 2026 EPS Estimate Revision Neutral Sentiment: Yahoo Finance ran an analysis on HALO’s recent share gains and its current valuation metrics. What Recent Gains Reveal About Its Current Valuation Neutral Sentiment: The company named Cortney Caudill as Chief Operating Officer, marking an executive leadership update. Halozyme names Cortney Caudill as COO Negative Sentiment: Zacks Research downgraded HALO from a “Strong-Buy” to a “Hold” rating, signaling reduced near-term bullish outlook. Halozyme Therapeutics Downgraded to Hold Posted 2h agoAI Generated. May Contain Errors. HALO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Halozyme Therapeutics (NASDAQ:HALO) Downgraded by Zacks Research to HoldOctober 8 at 7:52 AM | marketbeat.comZacks Research Analysts Increase Earnings Estimates for HALOOctober 8 at 7:47 AM | marketbeat.comHalozyme Therapeutics (HALO): What Recent Gains Reveal About Its Current ValuationOctober 8 at 4:45 AM | finance.yahoo.comHalozyme names Cortney Caudill as COOOctober 7 at 11:44 PM | msn.comHalozyme Appoints New Chief Operating OfficerOctober 7 at 2:25 AM | msn.comHalozyme Appoints New Chief Operating OfficerOctober 7 at 2:25 AM | msn.comFY2025 EPS Forecast for Halozyme Therapeutics Cut by AnalystOctober 6 at 2:16 AM | marketbeat.com33,600 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by LGT Fund Management Co Ltd.October 5 at 4:47 AM | marketbeat.com111 Capital Makes New Investment in Halozyme Therapeutics, Inc. $HALOOctober 5 at 4:39 AM | marketbeat.comWhat is Leerink Partnrs' Estimate for HALO FY2026 Earnings?October 5 at 2:21 AM | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 SharesOctober 4, 2025 | insidertrades.comHC Wainwright Boosts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $90.00October 4, 2025 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,380,600.00 in StockOctober 3, 2025 | marketbeat.comInsider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of StockOctober 3, 2025 | marketbeat.comResearch Analysts Set Expectations for HALO FY2026 EarningsOctober 3, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Acquires 38,049 Shares of Halozyme Therapeutics, Inc. $HALOOctober 3, 2025 | marketbeat.comHC Wainwright & Co. Maintains Halozyme Therapeutics (HALO) Buy RecommendationOctober 2, 2025 | msn.comHalozyme Therapeutics (NASDAQ:HALO) Trading Down 4.3% on Insider SellingOctober 2, 2025 | marketbeat.comHC Wainwright Increases Halozyme Therapeutics (NASDAQ:HALO) Price Target to $90.00October 2, 2025 | marketbeat.comHalozyme eyes microparticles in $900m Elektrofi acquisitionOctober 2, 2025 | finance.yahoo.comAMI Asset Management Corp Sells 16,475 Shares of Halozyme Therapeutics, Inc. $HALOOctober 2, 2025 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Director Sells $150,480.00 in StockOctober 2, 2025 | insidertrades.comBenchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price TargetOctober 2, 2025 | msn.comBernadette Connaughton Sells 2,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) StockOctober 1, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (HALO) M&A Call TranscriptOctober 1, 2025 | seekingalpha.comCalifornia company swoops in with $750M to buy Boston biotechOctober 1, 2025 | bizjournals.comHalozyme to acquire Elektrofi, a biopharma focused on drug deliveryOctober 1, 2025 | msn.comHalozyme to buy Elektrofi in up to $900 million deal to expand drug delivery lineupOctober 1, 2025 | msn.comHalozyme Therapeutics, Inc. (HALO) Discusses To Acquire Elektrofi Conference Call (Transcript)October 1, 2025 | seekingalpha.comHalozyme Therapeutics, Inc. (HALO) Elektrofi, Inc., M&A Call - SlideshowOctober 1, 2025 | seekingalpha.comHalozyme Therapeutics (NASDAQ:HALO) Updates FY 2025 Earnings GuidanceOctober 1, 2025 | marketbeat.comHalozyme to buy Elektrofi for $750 million to expand drug delivery lineupOctober 1, 2025 | reuters.comHalozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040sOctober 1, 2025 | prnewswire.comHalozyme Therapeutics, Inc. $HALO Shares Acquired by State of Alaska Department of RevenueOctober 1, 2025 | marketbeat.comHalozyme Therapeutics, Inc. $HALO Shares Sold by Fifth Third BancorpOctober 1, 2025 | marketbeat.comStocks With Rising Relative Strength: Beam TherapeuticsSeptember 30, 2025 | msn.comArcturus Therapeutics Earns Relative Strength Rating UpgradeSeptember 29, 2025 | msn.comCongress Asset Management Co. Sells 297,296 Shares of Halozyme Therapeutics, Inc. $HALOSeptember 26, 2025 | marketbeat.comHalozyme Therapeutics, Inc. $HALO Holdings Lowered by Ruffer LLPSeptember 25, 2025 | marketbeat.comNorden Group LLC Sells 3,457 Shares of Halozyme Therapeutics, Inc. $HALOSeptember 25, 2025 | marketbeat.comAkero Therapeutics Scores Relative Strength Rating Upgrade; Hits Key BenchmarkSeptember 24, 2025 | msn.comHalozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $90.00 at BenchmarkSeptember 24, 2025 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) CFO Sells $173,594.65 in StockSeptember 24, 2025 | insidertrades.comInsider Selling: Halozyme Therapeutics (NASDAQ:HALO) CFO Sells 2,227 Shares of StockSeptember 23, 2025 | marketbeat.comForecasting The Future: 7 Analyst Projections For Halozyme TherapeuticsSeptember 22, 2025 | benzinga.comHalozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, HC Wainwright Analyst SaysSeptember 22, 2025 | marketbeat.comSwedbank AB Sells 100,100 Shares of Halozyme Therapeutics, Inc. $HALOSeptember 22, 2025 | marketbeat.comShelton Wealth Management LLC Purchases Shares of 16,196 Halozyme Therapeutics, Inc. $HALOSeptember 21, 2025 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Sets New 1-Year High - Here's What HappenedSeptember 20, 2025 | marketbeat.comLivforsakringsbolaget Skandia Omsesidigt Acquires 44,700 Shares of Halozyme Therapeutics, Inc. $HALOSeptember 20, 2025 | marketbeat.com Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HALO Media Mentions By Week HALO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HALO News Sentiment▼0.590.63▲Average Medical News Sentiment HALO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HALO Articles This Week▼4016▲HALO Articles Average Week Get the Latest News and Ratings for HALO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Halozyme Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies BIIB News Today UTHR News Today INCY News Today NBIX News Today IONS News Today EXEL News Today EXAS News Today BMRN News Today MDGL News Today RGEN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HALO) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
